Medical Writing - Symposium Highlight
Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
Can chemotherapy be avoided in women with hormone-sensitive breast cancer? This is a prominent question in Hong Kong where breast cancer is the most prevalent malignancy among women and incidence is still on the rise.
Dr Richard Finn, Associate Professor of Medicine at the David Geffen School of Medicine (UCLA) gave an expert lecture on the use of CDK4/6 inhibition in breast cancer during an evening symposium held on the 22nd of May, 2017 organised by the Hong Kong Breast Cancer Foundation.
Dr Joanne Chiu, Clinical Assistant Professor and Deputy Medical Director of the Phase I Clinical Trials Centre at the University of Hong Kong shared the local experience on the use of CDK4/6 inhibitors.